Visitors register at the World Health Summit in Berlin under the banner “From Crisis to Resilience,” with over 4,000 visitors expected in person.
Visitors register at the World Health Summit in Berlin under the banner “From Crisis to Resilience,” with over 4,000 visitors expected in person.

BERLIN – The WHO Director-General election process ignited its first public candidate conversation on Sunday (11 October) at the 2026 World Health Summit in Berlin, as four of the race’s seven declared contenders tackled the thorny question of how to make global health institutions more responsive and fit for purpose.

The opening day’s flagship event on ‘global health architecture reform’ packed the auditorium to capacity – in a session widely perceived as the most significant of this year’s conference events.  But even if the candidates were prepared with ready prescriptions of ‘what’ reforms are needed – the ‘how’ to implement proved to be much more elusive, critics observed.

“The election of the next Director-General will take place at a pivotal moment for the World Health Organization and for global health more broadly,” declared World Health Summit President Dr Axel Pries at an opening press briefing Sunday, just ahead of the event.

“We are meeting at a moment when health around the world is under pressure from several directions – conflict and geopolitical tensions, economic strains, climate crisis, and increasing inequities,” Pries said at the opening of this year’s summit Sunday, just ahead of the panel event.

Held from 11-13 October this year under the theme “From Crisis to Resilience: Innovating for Health,” the summit has drawn over 4,000 in-person delegates to Germany’s capital as well as tens of thousands of online participants. Representing two-thirds of the world’s nations across more than 75 thematic sessions, delegates gather to debate pressing global health challenges and, crucially, the upcoming WHO Director-General election.

High stakes WHO Director-General election contest and empty chairs

WHO Director-General candidate panel (left to right): María Neira, Gevorg Tamamyan, Hanan Al-Kuwari, and Budi Gunadi Sadikin address the World Health Summit in Berlin.
WHO Director-General candidate panel (left to right): María Neira, Gevorg Tamamyan, Hanan Al-Kuwari, and Budi Gunadi Sadikin take questions from German diplomat and moderator Björn Kümmel at the World Health Summit in Berlin.

Responding to questions assigned by randomised lot by Björn Kümmel, a senior German Health Ministry advisor on global health and co-chair of the WHO-hosted task force on global health architecture reform, four prospective contestants took the stage to confront pressure to overhaul the world’s premier health agency: former Qatari Health Minister Dr Hanan Al-Kuwari, Indonesian Health Minister Budi Gunadi Sadikin, Spanish public health veteran Dr María Neira, and Armenian paediatric oncologist Dr Gevorg Tamamyan (nominated by Botswana).

Notably, three candidates were absent, including Saudi Arabia’s Dr Hanan Balkhy, stranded in Panama after an earthquake grounded her flight. Also missing – with no clear explanation as to why – was Belgium’s Dr Hans Kluge, and China’s Dr Song Li, whose nomination was only publicly confirmed last week.

The contestants directly addressed the high-stakes elephant in the room: an agency reeling from severe budget cuts and a 25 per cent workforce reduction following the withdrawal of the United States and member states’ demands for a restructured global health architecture that elevates country sovereignty and eliminates institutional overlap.

While senior observers pointed out that the exchange lacked deep specifics – cautioning that only four of the seven candidates were present to face scrutiny – the session nonetheless produced sharp contrasts. The contenders put forward distinct positions outlining how they intend to steer the organisation during their first 100 days in office.

Al Kuwari pledges executive review and functional reform

Dr Hanan Al Kuwari
Dr Hanan Al Kuwari

Former Qatari Health Minister Al-Kuwari offered a structured executive management approach to the WHO Director-General post, promising to eliminate administrative duplication across headquarters, regional offices, and country missions.

“Within my first 100 days, I will commission an independent functional review of the three levels of the organization and publish the findings,” she said.

She advocated for raising mandatory assessed contributions to 50 per cent of the base budget, securing flexible funding through the WHO Foundation, and establishing independent oversight over WHO’s scientific advice.

Neira focusses on primary prevention and environmental threats

Dr María Neira
Dr María Neira

Former Director of WHO’s Department of Environment, Climate Change and Health Dr María Neira advocated for a strategic pivot toward primary prevention, calling on governments to direct sovereign capital into clean water, air pollution abatement, and climate resilience to prevent illness before patients require hospitalization.

“We need a massive shift towards primary prevention -acting on the causes of disease before people become patients,” said Neira.

During her first 100 days in office, she pledged to motivate WHO staff and establish an early-warning “antenna” to detect emerging environmental and health risks, including microplastics, endocrine-disrupting chemicals, and declining global fertility rates. Underscoring that WHO’s authority rests on evidence rather than budget size, she maintained that the agency must serve as a scientifically fearless voice capable of influencing upstream investments across agriculture, energy, and urban planning – as well as better preparing health systems to address unavoidable disease burden.

Sadikin opts for unlocking financing for member state plans

Budi Gunadi Sadikin
Minister Budi Gunadi Sadikin

Former commercial banker and Indonesian health minister Sadikin argued that WHO must shed some of its broader operational functions to refocus strictly on its two constitutional mandates: scientific norm-setting and its unearmarked convening authority.

“When I talked to almost 100 health ministers across the world, the main message they gave me is to bring WHO back to its core mandate of setting norms and guidelines based on science,” he said.

Drawing on his experience co-chairing the Accra Reset High-Level Panel, he urged WHO to assist health ministries in converting national health plans into costed compacts that unlock development bank capital, while consolidating overlapping functions across global health initiatives. He emphasised that restoring internal credibility is an essential task for the next WHO Director-General to earn back flexible donor trust, maintaining that global health security ultimately requires keeping diplomatic doors open to all states.

Tamamyan puts patient outcomes over diplomatic protocol

Dr Gevorg Tamamyan
Dr Gevorg Tamamyan

Paediatric oncologist Tamamyan brought a clinician’s perspective to the stage, challenging conventional diplomatic protocol and demanding that WHO measure performance by patient health outcomes rather than process documents. He argued that WHO must never allow bureaucratic boundaries to obscure its ultimate moral purpose.

“We should be the place where anyone can call, can say, ‘Okay, I have this problem,’ even if it is not within our mandate, but we are able to help. We should not hesitate to take the call, to call someone we know and help,” he said.

Addressing the elephant in the room

Pledging to bring the United States and Argentina, which withdrew from the WHO in 2025, back into the fold of the UN specialized agency – Tamanyan said he would travel personally to Washington and Buenos Aires within his first 100 days to ask both member states to return. He insisted that WHO must do whatever it takes to protect health, even if it means stepping beyond formal constitutional boundaries to engage disaffected capitals.

Al-Kuwari, asked by Kümmel about how to maintain WHO’s credibility as a universal norm-setting body when major member states have retreated, took a more measured stance, saying: “WHO is richer with everybody being in the organisation and everyone having an equal voice.”

She argued that departed capitals “have more to gain than to lose by staying in the organisation,” noting that the structural changes they demand – such as eliminating duplication, increasing transparency, and enforcing accountability – are identical to the reforms requested by remaining member states. Instead of offering any particular set of concessions.

Analysts have cautioned that bold personal diplomacy alone cannot resolve deep geopolitical divides. “Bringing back departed Member States requires building an environment for genuine dialogue rather than making unilateral promises,” pointed out Michel Kazatchkine, former Global Fund Executive Director and senior fellow at the Geneva Graduate Institute, in an interview with Health Policy Watch.

Rebooting WHO after cutbacks

Asked how the candidate would remotivate WHO staff internally following a devastating year of cutbacks, Neira called for a fosteríng “a more creative internal environment” as well as ensuring that staff recruitment was “high quality” and independent.

Tamamyan said he’d focus on bringing more young professionals into the organization – the same group that bore the brunt of the recent, deep cuts in WHO staff over the past year.

Measuring success

Asked to summarize in just a sentence what success would look like by the end of the DG’s five-year term in 2032, Sadikin also referred to the US and Argentinian withdrawal saying, “what I envisioned is that all 194 countries will be back, and they will happily pay the assessment fee, and then they will proudly say that ‘Hey, WHO, you make our people live long and healthy.’”

For Al-Kuwari a successful team would mean that: “the world is healthier, it’s better prepared for emergencies, and it’s a fairer one.”

And for Neira, it would be “global health at the centre of government policy”  while Tamanyan said “for me the best achievement would again be about people” – adding that he wanted to also see a 90% satisfaction rating amongst the staff of WHO itself – as a reflection of success.

Candidate conversation was ‘high-level warm-up’

Michel Kazatchkine
Michel Kazatchkine

While praising the unscripted, randomised format, Kazatchkine stressed that candidates avoided debating the hard institutional trade-offs facing the agency, leaving the conversation high-level and mostly non-contentious.

“Everyone agrees that WHO should be normative. That means it should put science at the heart of everything it does, undisputable, unchallengeable science. Yet, they did not speak about science,” said Kazatchkine.

He pointed out that contenders sidestepped critical structural issues, including who should appoint Regional Directors, how regional offices interact with headquarters, and how WHO coordinates with regional bodies. He noted that while Regional Directors sit closer to Member States, the candidates offered no clarity on resolving structural friction across these tiers.

Many details of WHO’s own institutional reform will depend on how Assistant Directors-General are chosen.

“There was maybe a little too much pressure on the Director-General rather than on the team surrounding him,” said Kazatchkine.

Framing the Berlin WHO Director-General election panel as a good warm-up, he emphasised that observers must remain cautious in drawing conclusions at this stage.

Following the first stop in Berlin, the candidate field turns to the official WHO Candidates’ Forum in Geneva this November. The 34-member Executive Board will subsequently shortlist and nominate three finalists during its session in January 2027, ahead of the decisive World Health Assembly vote in May.

As WHO Nominations For Next Director-General Close, Six Contenders Emerge – But More May Remain Under Seal

Image Credits: Felix Sassmannshausen/HPW, Elaine Ruth Fletcher/HPW, Graduate Institute.

WHO Director Generals

The World Health Assembly chooses a new chief for the World Health Organization in May 2027. Before judging the candidates, assess the predecessors. Eight people have held the post over 78 years. Their varied track record offers pointers for selecting the  future incumbent.

Every five years, WHO rediscovers that its Director-Generalship is a political office metaphorically clad in a white coat. The search for Dr Tedros Adhanom Ghebreyesus’s successor is underway: six prospective candidates are publicly listed, others may stay sealed until November. The hopefuls will present their case in webcast member state hearings before the Executive Board shortlists three of them in February 2026. The 80th World Health Assembly makes the final selection by secret ballot next May.

Before judging them, it is worth assessing those who went before. Eight people have led WHO since 1948. Each inherited a different world and a different burden of disease, and each deserves to be measured against what their era made possible rather than against today’s hindsight. However, each is also culpable for legacies – direct or indirect – that create today’s challenges. 

Here is my reckoning, era by era, ending with a ranking.

Shaky foundation (1948–53): Brock Chisholm

Director-General Chisholm WHO
Dr Brock Chisholm of Canada, innagural Director-General of the WHO.

A psychiatrist and decorated soldier, Chisholm became Canada’s deputy health minister and Surgeon General before running the Interim Commission that created WHO and was elected its first Director-General. His constitutional legacy of semi-independent regional offices continues to bedevil the Organization today. 

His visionary fingerprints are all over WHO’s Constitution including a holistic definition of health that still survives. But he was an awkward prophet who once said that “one cultural anthropologist is worth more than 100 malaria teams”. He had already scandalised Canada by denouncing Santa Claus as an offence against clear thinking. Today we may appraise him as the first warrior against misinformation. 

His pioneering views around the social determinants to health were ahead of his times and he did not serve a second term; Ottawa was not keen that he should. Considering his era’s existential challenge – to build a universal health body as the Cold War froze and the Soviet bloc walked out – his assessors are harsh to cast him as “consistently mediocre” and “deservedly forgotten”.  

Though hugely unpopular inside and outside WHO, he kept the ship steaming along through the maddening political complexities of east–west animosity. He also seeded the ‘administering penicillin versus reducing poverty’ debate that continues to politicise global public health. 

Pragmatic consolidation (1953–73): Marcolino Candau

Director-General Marcolino Candau WHO
Dr Marcolino Candau of Brazil, the second WHO director-general from 1953-1973.

The Brazilian malariologist and public health physician was Chisholm’s Assistant Director-General before joining the Pan American Sanitary Bureau from where he was a surprise leadership choice over better-known rivals. 

Where Chisholm preached, Candau administered. Urbane, discreet and politically astute, he read the Cold War correctly. A universal agency could only survive bipolarity by being useful to all and threatening none.  So he took WHO firmly down the “magic bullet” track his predecessor had resisted. His 1955 bet on global malaria eradication coincided with American anxieties about communism in the tropics but had to be abandoned after DDT resistance, administrative fatigue, and exclusion of most of Africa.   

Bruised by this experience, he opposed smallpox eradication as failure would damage his beloved Organization. But with the Soviets pushing, the divided WHA approved the smallpox bet in 1966 by a mere two votes. The reluctant Candau put an American in charge so that Washington would carry the blame of anticipated failure. He was proved wrong in due course. 

Candau saw to the first International Health Regulations in 1969 – and clashed with member states when he reported Guinea’s 1970 cholera outbreak prior to its government doing so. Here, a patient receives care at the cholera treatment centre, Gadarif, Sudan, in October 2023.

His era’s existential test was absorption: decolonisation delivered 57 new member states and the Soviet bloc returned. Despite scepticism, Candau kept all on board. Perhaps that kept him too busy to formulate his health doctrine, and so,  articulating the systematic foundations of comprehensive healthcare had to wait. 

The collateral consequence was that the vertical-versus-horizontal argument, the trade-off between eradicating one disease or strengthening whole systems, became further entrenched, and continues to confound global health today. 

Meanwhile, he ushered in the International Health Regulations in 1969 along with a foretaste of battles ahead when members condemned his unilateral decision to expose Guinea’s 1970 cholera outbreak. 

Candau served for a record twenty years to build the administrative house in which Mahler’s revolution could be staged. The Royal College of Physicians’ verdict is fair: he turned a struggling agency into one of  influence and concrete achievement.

Moral ascendancy (1973–88): Halfdan Mahler

Dr Halfdan MahlerDirector General WHO
Dr Halfdan Mahler of Denmark, served as WHO director-general from 1973-1988.

A Danish tuberculosis specialist, Mahler was profoundly shaped by his Red Cross work in Ecuador and with India’s national tuberculosis programme. 

He gave WHO its moral height. The first essential medicines list in 1977, the “Health for All (HFA)” declaration in 1978, smallpox eradication in 1980, and adoption of the code on breast-milk substitutes in 1981 (with the United States as the sole vote against) were landscape-shifting advances as Mahler picked up Chisholm’s social medicine banner to storm over opposing ramparts. 

But this deepened the ideological rift between European socialised medicine traditions and American free-marketeers. This was not helped by the symbolism that the health-for-all gauntlet was thrown from Alma Ata (now Almaty) in the Soviet Union. And so, the Europe-and-Third-World dominated comprehensive ambition WHO was pitted against the American-dominated UNICEF’s selective child survival prescription. 

Thus ensued a mighty battle for global health leadership between WHO and UNICEF, egged on by their respective cheerleaders. That lasted for decades right into the current era and fractured multilateralism while seriously confusing national health debates.

Washington’s anger was soon evident in its 1985 refusal to pay its assessed dues. WHO’s budget crisis that followed established a precedent that got repeated.   

Mahler oversaw a defining moment in global health: the eradication of smallpox. Eradication was certified by the Global Commission, an independent panel of scientists drawn from 19 nations, in December 1979 at WHO Headquarters, Geneva.

Mahler’s HFA was buried under the disease-specific Millennium Development Goals during the time of UN Secretary General Kofi Annan, himself a former WHO employee. But then resurrected as Universal Health Coverage in the 2015 Sustainable Development Goals.

For the record,  Mahler was not always right. He badly misread the century’s defining epidemic saying that AIDS should not receive excessive attention. But, with his trademark grace, he later admitted his mistake.

Although Mahler himself acknowledged that health for all would not be achieved by his target date of 2000, he quipped, “we will have fun trying”. And therein lies the secret of his success as the only director general who was both popular and respected.  The preacher’s son purposefully deployed his moral authority to fundamentally change what the world thinks health is for.

I have a personal confession: Mahler was the direct inspiration for my own early career choices.  

Trust squandered (1988–98): Hiroshi Nakajima

Dr Hiroshi Nakajima of Japan, served as WHO director-general from 1988-1998.

The Japanese psychopharmacologist directed WHO’s Western Pacific region, before becoming the Organization’s first Asian chief. This was over American objections, the divided Executive Board preferring Nakajima in rebuke to Western ownership of the office.

He inherited the AIDS pandemic and the post-Cold-War moment when health could have claimed its rightful place in the new world order. He lost both struggles. 

His clashes with Jonathan Mann, the charismatic head of the Global Programme on AIDS, ended in Mann’s resignation in 1990 and, by 1996, the condition was removed from WHO’s hands and given to the new UNAIDS. (For transparency: I was secretary to the international commission that engineered this).

Meanwhile, the World Bank, armed with the powerful 1993 report, Investing in Health, became the intellectual centre of global health, and donors followed their money there.

His 1993 re-election was the nadir. He dismissed Mohamed Abdelmoumène, the deputy daring to run against him. Nevertheless, Nakajima was re-nominated by the Board amid allegations that Japan had awarded research contracts to 23 of the 31 Board members who supported him. The Assembly re-elected him 93-58 on developing country votes over open Western opposition. The external auditor resigned and organisational reputation was severely damaged. In 1995, Nakajima questioned whether Africans could write proposals and had to apologise.

Nevertheless, important WHO programmes continued to trundle along, the Global Polio Eradication Initiative got underway, and the DOTS tuberculosis strategy was launched. 

Despite the turmoil of Nakajima’s tenure, WHO issued the DOTS programme which became the international standard for tuberculosis treatment.

But overall WHO regressed over Nakajima’s divisive decade. The costly lesson is that competent machinery eventually succumbs to the collapse of trust in the person at the top. 

Revival (1998–2003): Gro Harlem Brundtland 

Dr Gro Harlem WHO DG
Dr Gro Harlem Brundtland of Norway, served as WHO director-general from 1998-2003.

The answer to Nakajima was to reach higher. Brundtland, a physician by training, was Norway’s three-time prime minister and chaired the iconic commission that gave the world “sustainable development”. She was the first woman and first head of government to take the post. She arrived as a political heavyweight and governed like one.

She purged and restructured headquarters, recruited stars, and went where the money was. Her Commission on Macroeconomics and Health, reclaimed some thought leadership. Her major triumph was the first ever treaty negotiated under WHO’s constitution: the Framework Convention on Tobacco Control, adopted unanimously in 2003.  

She issued the first travel advisories in WHO history. First, against China which she publicly rebuked for concealing SARS. It contributed to the sackings of the Chinese health minister and the Mayor of Beijing. She followed up by defying Canada’s fury over advisories against travel to Toronto. 

Her science-informed even-handedness won respect without repercussions from the great powers that was to become their future mode. (Another personal confession: she tried to persuade me to take a directing role for a new health emergencies function but I had a parallel offer from the UN to head its Sudan operations and preferred the field to sitting in Geneva). 

Brundtland’s vision for global health was bigger than parochial WHO institutional interests.  But this necessitated a difficult bargain. She inherited a broke, distrusted, and sidelined Organization. The World Bank had more ideas and money as donors had stopped believing that WHO could spend well. Her reaction was not to repair WHO’s core but to go around it: she built new vehicles that donors would fund precisely because they were not WHO. Roll Back Malaria and Stop TB were partnerships hosted at WHO but governed by their funders. GAVI (2000) and the Global Fund (2002) were set up as separate institutions. 

Brundtland’s legacy includes mediating the first ever treaty under WHO’s consititution: the Framework Convention on Tobacco Control.

The bargain she struck was paid over subsequent decades as earmarked voluntary contributions for donor-favoured programmes took precedence over assessed dues. That distorted WHO’s core functions. COVAX in 2020 was an example of “authority without instruments”: WHO co-led an initiative it could not control and was blamed for its failures anyway.

But Brundtland undoubtedly galvanised countries. Her 2000 World Health Report that ranked national health systems – France first, the United States 37th – delighted media and public but outraged ministries as invidious “health Olympics”. The Executive Board balked at its repetition and it became diluted into today’s mind-numbing Universal Health Coverage index.

Then, after refusing a second term that was hers for the asking, the colossus retired. Admirers saw dignity in this while critics saw a politician who had restored the stage but left before the chickens could come home to roost. Either way, she proved something her successors have struggled with: her high office could assert one day and remain standing the day after. 

Unfinished promise (2003–06): Lee Jong-wook

Dr Jong Wook Lee WHO DG
Dr Lee Jong Wook of South Korea, was WHO director-general from 2003-2006.

The South Korean physician had already spent twenty years inside WHO – on leprosy in the South Pacific, and then in vaccines and TB – before squeaking into the top job by a single switched vote. 

He was a man of forthright convictions saying that the world needed leadership in the struggle for “security from infections, and justice for those worst affected by diseases of poverty.” In practice, he was a consummate but quiet campaigner who traded constantly with the United States to keep the Bush administration’s money and patience.

He felt the need to prove something fast. On World AIDS Day 2003 he launched “3 by 5” — three million people in developing countries on antiretroviral treatment by the end of 2005. He was warned that he would be blamed for likely failure. Nevertheless, he committed $300 million of WHO’s own budget and demanded that every technical programme contribute. (That is how I found myself working on HIV and humanitarian programming in WHO Geneva in 2005 when I became a “refugee” from the United Nations after my role leading UN Sudan ended in the blood and tears of the Darfur genocide).  

Although Lee’s AIDS target was missed (roughly 1.3 million were on treatment by the deadline), the failure was of the type that changes the world. It broke the taboo that treatment in poor countries was unaffordable and paved the way for the G8’s 2005 commitment to universal access by 2010. He was the first Director-General to meet AIDS activists face to face.

WHO under Lee Jong-Wook launched the ambitious “3 by 5” programme on World AIDS Day 2003 – to get three million people in developing countries on HIV antiretroviral treatment by the end of 2005.

Two other foundations outlasted him. In 2005, WHA adopted the revised International Health Regulations, converting Brundtland’s SARS improvisations into international health law and giving WHO the right to act on unofficial intelligence. And his Commission on Social Determinants of Health, picked up Mahler’s banner  to power the equity language that  saturates global health nowadays. He also took the pandemic influenza threat seriously before that was fashionable, and committed WHO to transparency and accountability in ways his predecessors had not.

One of his biggest tests was the 2004 Indian Ocean Tsunami which exposed internal senior management faultlines around whether a norm-setting body should get its hands dirty with running  emergency field programmes. (That is how I shifted from HIV to become WHO’s director of emergency response). The debate progressively resolved under his successors with member states demanding  proactive WHO support during disasters and crises, but it still causes organisational tension. 

Lee died suddenly and tragically as the 2006 WHA opened, his mandate unfulfilled. What remains is the record of a quiet and cultured man of under-estimated humanity who courageously chose the hardest target available and was proved right by his own failure.

Contained decline (2007–17): Margaret Chan

Dr Margaret Chan of China, served as WHO director-general from 2007-2017.

The answer to Lee’s death was Asian continuity with Chinese characteristics. This was Beijing’s first bid for a weighty UN agency. Chan had been Hong Kong’s Director of Health through the 1997 bird-flu cull and SARS in 2003, before Geneva brought her for environment and then communicable diseases. A Hong Kong legislative inquiry had found her SARS performance wanting but she got hired anyway, perhaps because she was the only person who had actually managed such crises. 

She asked to be judged by two measures: the health of Africans and of women. Neither became her legacy but she walked into the trap that often defines the office: deciding, under uncertainty, whether a new outbreak is a global emergency with the office paying whichever way the call goes.

In June 2009 she declared the H1N1 pandemic, the first in forty years. The virus proved mild, governments were left with warehouses of vaccine, and WHO was accused  of making a “false pandemic” that profited pharma. Five years later she over-corrected when it took a thousand Ebola deaths and regional spread before she declared an emergency. Médecins Sans Frontières charged WHO with inaction and ineptitude  – a judgement I could validate from my own independent visit to West Africa.  

Chan’s defence that WHO is a technical agency and governments carry the first responsibility was the bureaucrat’s answer to the question Lee had left open. Member states firmly rejected this and forced her to quicken the pace to establish, in 2016, the Organization’s operational arm, the Health Emergencies Programme.

H1N1
WHO under Chan was accused of making a H1N1 a “false pandemic.” Five years later she over-corrected when it took a thousand Ebola deaths and regional spread before she declared an emergency.

Declining confidence in Chan fed quickly into WHO’s decline, even as leading analysts and governments debated whether to establish a new public health emergencies organisation. 

Emergencies – when donor purse-strings open – are often how agencies top up their budgets but few were keen to give to WHO. Meanwhile, the 2011 financial crisis forced the deepest cuts since Nakajima. 

Chan’s management of organisational decline was criticised as failing to see that business as usual was over. In a telling comment, the chair of WHO’s audit committee said the agency often did little to stop misbehaviour. And the press revealed that WHO spent more on travel than on AIDS, TB, and malaria.

Nevertheless, there were some results.  She made universal health coverage WHO’s organising idea, carried the non-communicable disease agenda to the UN General Assembly, and backed countries defending the tobacco treaty against industry litigation. 

Unthreatening to Beijing or Washington, the geopolitics of the era got what it wanted: someone contained. Wrong-footed by both great crises of her time, she survived two full terms but bequeathed an Organization of sharply diminished authority.

Geopolitical rupture (2017–27): Tedros Adhanom Ghebreyesus

Tedros demands urgent digital governance.
Tedros who served as Ethiopia’s health and later as foreign minister, faced mounting geopolitical pressure in the past decade.

The answer to Chan was to break the mould. Tedros Adhanom Ghebreyesus is the first African, the first non-physician, and the first chosen by the whole membership by a convincing majority, rather than a Board deal. (Transparency declaration: I was involved in his campaign).  

A malariologist with a doctorate in community health, he had been Ethiopia’s health, and then foreign minister. With a politician’s résumé and a campaigner’s instincts, he is the first DG since Brundtland to understand that the office is won and kept via capitals, not laboratories.

He has governed the hardest decade since WHO’s founding and his reactions demonstrate both his stature and his limits.  

COVID-19 brought him the Chan trap at planetary scale. He declared the emergency on 30 January 2020, earlier than most governments acted. But he had also praised Beijing’s transparency days before, and the two facts were weaponised against each other. 

Washington under Trump withheld funds and announced withdrawal but reversed under Biden before withdrawing for good in 2026 when Trump returned.  An independent commission found that 21 of 83 alleged perpetrators of sexual abuse during the 2018–20 Congo Ebola response were WHO staff, the worst institutional scandal in the Organization’s history. The response was bureaucratically correct but somehow lacked feeling. 

He made a few astonishing mis-steps such as appointing the 93-year-old Zimbabwean dictator Robert Mugabe as WHO Goodwill Ambassador on NCDs. Critics wondered if this was repaying an election debt: Mugabe headed the African Union when the bloc endorsed Tedros over other African candidates for the top post, without any real regional contest. A furious world forced Tedros to retract. 

Health workers at the DRC’s Rwampara Ebola Treatment Center put on their personal protective equipment in the isolation area before entering in May 2026.

In 2022 he overruled his own emergency committee to declare mpox an emergency, the first DG to do so. He was also very quick this year to  declare DRC’s 17th Ebola outbreak as a public health emergency of international concern. The Chan lesson had been learnt. But as the Bundibugyo Ebola spread outpaces response there is criticism of the adequacy of WHO response. 

Gaza tested a different nerve. Tedros called on Israel to stop attacking hospitals, mistreating humanitarian staff including from WHO, and demanded a ceasefire and more aid to be let in. Earlier he had himself escaped a bad end when Israel bombed Sana’a airport as he waited to board.

With his numerous field visits, no Director-General has been so personally exposed to the wars he speaks about, nor so accused of taking sides in them. Israel and its supporters charged WHO with parroting Hamas-run ministry figures and ignoring its military use of hospitals.

WHO surveys destruction around Northern Gaza hospitals in March 2024.

However, the sharpest dissension was with his own country. Tedros is from the Tigray region and sat on the executive of the Tigray People’s Liberation Front, the party that ran Ethiopia for three decades, until he left for Geneva. When Abiy Ahmed’s government went to war with Tigray in November 2020, the Ethiopian military accused Tedros of helping TPLF and called for his removal. In January 2022, after Tedros described conditions in Tigray as “hell” and accused Addis Ababa of blocking medicine, Ethiopia asked WHO to investigate its own chief for misconduct. 

Ethiopia withheld nominating him for a second term  and the Nakajima question of the 1990s came to the fore: can the office survive a collapse of trust in the person holding it?  This time, the answer was very different: 28 other countries put him forward and he was re-elected unopposed.  

The war has touched Tedros deeply. He has lost relatives and his extended family in Ethiopia has been victimised.  He has been unable to go home for several years; it is doubtful if he will be able to do so when he finishes his term next year. 

German Health Minister Nina Warken (left) maintains that the Pandemic Hub remains a strategic priority (here at a meeting with WHO Director-General Dr Tedros (right) in May 2025).
Tedros’s legacy includes delivering the Pandemic Agreement in May 2025. He is seen here signing the agreement with German Health Minister Nina Warken (left) in May 2025.

Tedros has logged substantial entries on his ledger. He persuaded Member States in 2022 to raise assessed contributions towards half the budget by 2030 — the first serious attempt to buy back the autonomy Brundtland mortgaged. He delivered the Pandemic Agreement in May 2025, the second instrument negotiated under Article 19 of the WHO Constitution, though its pathogen-sharing annex remains mired in argument. He steered the 2024 amendments to the International Health Regulations. He has even managed to strengthen momentum on other challenges such as non-communicable diseases and mental health. 

Most of all, he has made WHO visible: no predecessor has been so present on screens and social media. A vital contribution to global health at a time of record levels of misinformation, vaccine scepticism, and conspiracy theories of many types. But, by the same token, his reward is to be personally attacked with a degree of venom rarely seen before.

WHO leadership, including Tedros and Dr Mike Ryan, are evacuated by helicopter from the DRC in 2019 after attacks against Ebola vaccinations. Ryan attends to a health worker wounded in the attack against the vaccination team. 

The US departure and other donor aid cuts  leave an Organization whose base budget has been cut from $5.3 billion to $4.2 billion. Tedros’s reform efforts have been criticised. Because in the early part of his tenure, he allowed the organisation to grow too much and become top heavy and now risks hollowing-out with a quarter of  staff gone. 

He has also been handicapped by the uneven functioning of his regional offices that removed the discredited leaders of the Western Pacific  Regional Office and South- East Asia Regional Office. Tedros’s handling testifies to his political finesse but exposes the limits of his authority. He could not himself fire either regional directors. The governance contradictions that he inherited will pass on to his successor. 

Overall, however, Tedros will be admired for his leadership-from-the front through thick-and-thin. His undoubted major advancements deserve to outweigh his few mis-steps.  

But history can be cruel with a legacy often determined by an incumbent ‘s fading years rather than earlier achievements. He was propelled into office on the wave of disappointment with his predecessor’s failure on the West African Ebola outbreak. There is a risk that he may be seen out by his own struggling DRC Ebola response. 

The Director-General ranking

Dr Tedros at the 2024 World Health Summit in Berlin. Hanan Balkhy, currently listed as speaker in her role as Regional Director, must withdraw from official public appearances.
Dr Tedros at the 2024 World Health Summit in Berlin.

Now to a strategic weighing of each Director-General against what their era demanded, permitted and expected. Rankings of this kind are a judgement, not a scorecard. Mine rests on my personal exposure to several DGs and on four tests: 

Did they read their era correctly – the disease burden, the geopolitics, the money – and choose the fight that mattered? 

Did they build something that outlasted them, whether an idea, an instrument or an institution? 

What did they break, lose or leave undone, and were their failures forced by circumstance or misjudgement? 

And did they leave the office itself stronger or weaker than they found it: in authority,  independence, and the trust of those who fund and staff it? 

I have weighed a crisis survived above a programme launched, and a precedent set above a target met because the Director General is ultimately tested by the unforeseen far more than by the planned. Gender and geographical identity have no bearing on performance but personal character and conduct counts, as it must for a post whose only real asset is credibility. 

On those considerations, an obvious ranking emerges:

  1. Mahler brought moral authority to change what the world thinks health is for. 
  2. Brundtland proved that the office can lead and still survive to flourish.
  3. Candau built the Organization’s lasting foundations.  
  4. Tedros brought resilient leadership to confront our most toxic challenges. 
  5. Lee courageously pioneered attention for the most friendless causes of his day.
  6. Chisholm kept the ship afloat un-appreciated by his own creation that outgrew him.
  7. Chan played safe, was wrong-footed anyway, and ultimately disappointed.
  8. Nakajima brought WHO to its lowest point and is the warning for every DG aspirant.

This pattern should both inspire and trouble DG aspirants and their electors. The two at the top were not the obvious candidates of their day: a tuberculosis man from the field, and a politician who had left medicine behind. Both were, at some point, the most powerful member state’s least favourite official, but managed to leave on their own terms. 

The two at the bottom satisfied every criterion on paper and won two elections. But they ultimately failed with were politely ushered off the world stage. 

Between them lie a founder his creation outgrew, a builder whose greatest triumph was voted through over his objections, a reformer who died with his mandate unfulfilled,  and an incumbent whose legacy may yet be decided by a runaway epidemic. Mixed scorecards. 

It appears that the office rewards nerve over credentials and is forged in the crucible of outside forces. None of this is captured by the official criteria to select the next DG. Part II will ask what this should mean for the Assembly’s pick next May.

Mukesh Kapila

 

Mukesh Kapila is professor emeritus of global health and humanitarian affairs at the University of Manchester, and a board member of Health Policy Watch. Vital Signs in Global Health is a regular column, and the opinions expressed are solely those of the author. 

Image Credits: WHO, WHO/A. Kheir, WHO, Socios en Salud , WHO, WHO, Kerry Cullinan, Britannica , WHO/Christopher Black , Anicet Kimonyo, WHO , WHO/Christopher Black , Lindsay Mackenzie/ WHO, WHO/Marcio Schimming .

There were 361 open cases of claims of misconduct against persons – including sexual misconduct and other forms of harassment – in WHO worldwide, as of end August: WHO Dashboard

More sexual misconduct and abusive claims were filed against WHO staff, than closed, over the previous month – with 361 open cases in 2026, as of the beginning of September, according to the agency’s own investigations dashboard.

In August, the last month reported, investigators opened 37 new sexual and abusive conduct cases and closed 25 – representing a 25% increase in the queue in just the past month. The overall pace of case openings is running at an average of 28 a month, according to the WHO misconduct dashboard, run by the Office of Internal Oversight Services (IOS).

The data coincides with anecdotal staff reports of lagging investigations and an internal WHO auditor’s review reporting months of delay in case resolution and closures in 2025 – well beyond the three month/120 day target for investigations set by WHO following reforms made after the 2020 sexual harassment and abuse scandal involving WHO and UN staff and contractors, which surfaced in the Democratic Republic of Congo. 

Incorrect data on trends: WHO has acknowledged but failed to correct

Incorrect data on overall trends – which WHO has acknowledged but so far failed to correct – confounds any complete reading on how and where new cases are rising overall. 

“IOS’s abuse dashboards are actively reporting demonstrably false data. As of October 7, WHO finally flagged the charts for verification and added a brief note to the dashboard. It took external intervention to get action,” said Kieran Bligh, a global health researcher at George Washington University in a LinkedIn post.

“So far in 2026, only six sexual and abusive conduct cases have resulted in substantiated disciplinary decisions,” he added, citing WHO’s own reports. “Four involved senior personnel. Not one was dismissed.” 

Queried repeatedly by Health Policy Watch over the past week, WHO posted a note on the dashboard pointing to the errors, but failed to provide any further clarification about the data and trends.

Recruitment of new IOS Director pending

The imbroglio coincides with the WHO’s recruitment of a new IOS director, following the recent retirement of Lisa McClennon who held the post since 2023. 

Currently,  Malika Parent-AiT-Mohamed is serving as acting director – and may be a candidate for the fixed term post.  However, in light of the reportedly high rate of complaints, backlog of cases, and the sensitivity of the post, critics like Bligh, have called for more active supervision of the candidate selection process by the Executive Board.  

Among the seven contenders that have so far emerged since nominations closed on 24 September, only one has publicly addressed the issue. 

George Tamamyan, an Armenian oncologist nominated by Botswana, had his campaign team  analyse publicly available data in the May 2026 Internal Auditor’s report. In a lengthy LinkedIn post, he called upon victims and critics to approach him personally on the issue, saying:  

“What we found deserves a serious conversation. WHO reported that its investigations function handled 1,174 cases in 2025 and closed 636, leaving 538 at year-end….WHO says that timeliness, responsiveness and fairness in misconduct investigations are essential to maintaining trust. I agree!   

Declining case closures?

The ‘other’ category of WHO offices, typically referring to WHO’s Global Service Center, Kuala Lumpur, Malaysia, reported the highest number of sexual misconduct cases over the past 12 months.

What seems clear  is that over the past 12 months, a total of 336 cases of sexual misconduct or abusive conduct cases were filed across all WHO regions – with the lion’s share in Africa (69) and the Eastern Mediterranean Region (81). 

The same three topped the table in 2023, in the same order. Roughly a quarter of all open cases concern sexual misconduct. In Africa it is close to half.

“Other” WHO offices (typically referring to WHO’s global service center in Kuala Lumpur) and Headquarters ranked third and fourth in the number of sexual and general misconduct cases filed, with 27 sexual misconduct cases in the “other” category – the most of any.   

Fewer sexual misconduct and abusive conduct cases were closed in 2026 and 2025, as compared to 2024 – although far more than in 2021 and 2022, when the initial DRC revelations came to light. 

Sexual harassment in 2026 complaints outpace last year’s

WHO dashboard shows an uptick in sexual harrassment complaints in the first three quarters of 2026, as compared to all of 2025.

And with one-third of the year yet to be recorded, sexual harassment complaints had already passed last year’s total of 25, with a third of the year still to run.

Twenty months for a four-month job

WHO Internal Auditor Report to the May 2026 Assembly

In 2025, a sexual misconduct investigation took 20 months on average. WHO’s target is four, according to the  Internal Auditor’s report to the World Health Assembly in May. The wait was five months longer than a year earlier.

Abusive conduct, which covers harassment, discrimination and abuse of authority, was slower still. Together with financial cases it averaged 34 months against a target of six, according to the auditor’s report to the May 2026 World Health Assembly.

The office doing the work is shrinking. During the massive budget cuts seen over the past year, it discontinued nine vacant posts and ended 12 consultancy contracts, leaving 10.5 budgeted staff posts and about 10 full-time consultants. Along with the current screening for a permanent head of IOS, candidates for the permanent position of Head of Investigations.

“Overreliance on external investigators directly exposes cases at intake or investigation to delays owing to mandatory breaks in consultant contracts, natural attrition and turnover,” the auditors wrote. They called the caseload “not sustainable” under the current model.

The report also logged a steep fall in new sexual misconduct cases, to 48 in 2025 from 99 in 2024 and 172 two years before. Among the possible explanations it offered was “shifting attention and pressures” caused by WHO’s own restructuring. 

But this year’s dashboard numbers, however incomplete, suggest the lull could be over.

“Justice delayed is justice denied”

Internal report to the 2026 WHA on all types of misconduct, open and closed cases

Staff representatives have long complained about delays in WHO’s internal justice process. 

“Delays in justice processes not only undermine confidence in the system but also contribute to stress, disengagement and a sense of vulnerability among staff,” the WHO Staff Associations told the Executive Board at their meeting in February 2026. “As the saying goes, justice delayed is justice denied.”

The promise they are measuring against dates from the sex-for-jobs scandal in the Democratic Republic of Congo during the 2018–2020 Ebola response, when WHO admitted its failures and WHO Director General Dr Tedros Adhanom Gheybreysus pledged zero tolerance for abuse cases.

On a visit to the Goma, DRC in November 2022, then-WHO official Gaya Gamhewage committed to supporting survivors of sexual assault of the Ebola outbreak.

By May 2023, WHO was presenting the problem as under control. Its dashboard that month said a dedicated team had “cleared the SEA/SH backlog” and that sexual misconduct cases were being “worked in real time”, with “an end-to-end investigative process of 120 days”. It showed 426 open cases.

“WHO is committed to transparency in its zero tolerance approach to sexual misconduct,” the UN’s health body said during investigations of DRC abuses.

But three years on, the open count has fallen by just 65 cases, and the 120-day process has become a 20-month average.

One feature has not changed. A Health Policy Watch investigation in 2023 found that in the most serious cases the final decision following an IOS investigation and report rests with one person: the Director-General. In other cases, decision rests with the WHO Regional Director  – who 

In May, WHO issued a new strategy, Zero Tolerance in Practice, for 2026–2029. It promises zero tolerance for misconduct, for retaliation and for inaction. A companion dashboard tracks disciplinary measures since 2022. Zero tolerance for inaction sits awkwardly beside a 20-month wait.

For six candidates, few answers

“Zero tolerance cannot be a slogan,” said Tamamyan in his post, which also provided a graphic analysis of data from the Internal Auditor’s report on “financial, sexual and harassment cases filed and addressed last year. “It has to be measurable: Do people trust the system enough to report? Are those who report protected? Do victims and survivors receive timely, effective support? And when something goes wrong, do we learn from it, or simply close the file?” 

Post on the misconduct data by WHO candidate for Director General, Gevorg Tamamyan

The six DG contenders who so far have remained mum on the issue include: Hans Kluge of Belgium, WHO Regional Director for Europe; Hanan Balkhy of Saudi Arabia, Regional Director for the Eastern Mediterranean; Indonesian health minister Budi Gunadi Sadikin; Qatar’s former health minister Hanan Al Kuwari; Spain’s María Neira, a WHO director for two decades; and China’s Song Li, former Director of China’s Commission on Maternal and Child Health. WHO publishes the official list in November.

Three are WHO insiders. Two run regions that appear on the dashboard: Balkhy’s has the largest open caseload of all, Kluge’s one of the smaller. Investigations are run centrally by IOS, not by regional offices, and cases are counted by where they arise, not by who is responsible. But both know the system from the inside.

On the campaign trail the talk has been of money and structure. Kluge has called WHO “overstretched, under-focused, and overly bureaucratic”. Balkhy has asked: “How do we use our money better?”

And other than Tamamyan, none of the candidates’ published statements reviewed for this article mentions investigations, internal justice or protection for staff who report abuse.

They will get their chance. The first Candidates’ Forum is on 18 November in Geneva. The Executive Board shortlists up to three names in January, and the World Health Assembly votes in May 2027.

The winner takes office on 16 August 2027. With the job comes the final say on every serious misconduct case in the organization, and a queue that is still getting longer.

Image Credits: WHO , WHO Misconduct against Persons Dashboard, WHO, Misconduct Dashboard , WHO, Internal Auditor Report, WHO, Internal Auditor's Report to WHA, WHO, LinkedIn/Gevorg Tamamyan.

When the United States turned on the World Health Organization (WHO) in 2020, Germany came to its defence. It led a reform that will raise assessed, unearmarked contributions in steps to half of the WHO’s core budget by 2030, so that the organisation can spend more on collective priorities and less on projects favoured by powerful donors.

The WHO lists Germany as its largest donor in 2020-21 and second largest since. Those days are ending. The Bundestag is considering a 2027 budget that grows by almost 6%, mostly for defence, while cutting the health ministry’s operational fund to strengthen international health by 15.3%, from €55.9 million to €47.33 million.

Of the $262 million Germany pledged to the WHO at the 2024 World Health Summit, only a third has been budgeted.

This week, Berlin hosts the World Health Summit again. The host arrives with no working strategy, no ministerial coordinator, no parliamentary committee and no candidate to lead the WHO. France has an ambassador for global health. Britain has a development minister who describes her job as “security through solidarity.” Germany has a summit.

How did the country that defended the WHO end up here? “Germany is very bad at strategic planning,” Olumide Abimbola of the Africa Policy Research Institute told me. “Very bad.”

The record bears him out. Germany never had a grand plan for global health. It responded to Ebola, then to COVID, spent the money, and wrote the strategy afterwards. Under Scholz the chancellery stopped making the case; under Merz global health has become a budget line to be cut.

That is not a choice the world’s third-largest economy should make quietly. Germany has the money, the institutions and, since the United States stepped back, the opportunity to be a force for good in global health. It also has a direct interest in doing so.

Aid cuts, or a conference?

The World Health Summit, kicking off in Berlin on Sunday, has been hosted by Germany since 2009.

The stakes for Germany are not as abstract as they may seem. Mosquito-borne West Nile virus infections have been established in Germany since 2019. Two Frankfurt airport workers died of malaria this summer. German hospitals depend on doctors from Syria and Iraq and nurses from the Philippines and Kerala. Stuttgart’s Robert-Bosch-Krankenhaus employs staff from 86 nationalities and could not operate without them, its chief executive told me.

When COVID showed how closely Germany and the Western Balkans are bound by labour migration, part of the answer was to help build testing capacity there. A public health system, as an official at the Robert Koch Institute put it to me, cannot simply be switched on when it is needed. It has to exist before the crisis arrives.

Angela Merkel understood this. Her government put health on the G7 agenda in 2015 and the G20 agenda in 2017. Berlin secured the WHO’s pandemic intelligence hub, funded at €30 million a year; established a Global Health Hub for government, industry, science and civil society; and transformed the annual World Health Summit.

After Ebola, parliament expanded the mandate of the Robert Koch Institute. Its international centre became a technical partner to the public health institutes of Nigeria and Namibia and to Africa CDC.

Who runs the strategy?

German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine.

But Germany did not make these institutions durable. They rested on a scientist chancellor, a physician chief of staff and a few motivated officials in the health ministry.  When the chancellor left, there was little to keep the policy moving.

Stella Merendino, an emergency nurse who sits for Die Linke on the Bundestag’s health committee, draws the lesson: “A global health policy shouldn’t depend on whether a handful of MPs or officials happen to care about it. It needs structures, funding and political accountability.”

Today, seven ministries divide global health between them. Health deals with the WHO, Development with international funds, Research with laboratories, Justice with patents and Trade with markets. The Federal Chancellery does not referee.

The Foreign Office’s coordinator for global health, created after Ebola, is gone. Health now sits in a division whose remit reads “economy, development, health and UN budget.” The Bundestag allowed its global health subcommittee to lapse after the 2025 election. Germany’s 2020 global health strategy runs to 2030. Its mid-term review, published last November, sets no clear milestones.

Andreas Wulf of Medico International was not surprised: “If you don’t have milestones and goalposts, what is the review doing?” The problem is not a lack of institutions. It is the lack of a clear direction for using them.

Are German ministries working against each other?

German Health Minister Nina Warken addresses the World Health Summit in Berlin.

In January, the development ministry’s reform plan ended bilateral health cooperation with partner countries and described the ministry as “very consciously using its policy of cooperation as a geopolitical instrument.” The RKI’s technical work remains, at roughly €15 million a year across all sources.

The coalition had already dropped the 0.7% aid target, for the first time in three decades. German funding for the WHO’s pandemic intelligence hub was halved last year and stays halved.

Recently, the Accra Reset, an initiative by African and Asian governments on health sovereignty, listed Gavi, the Global Fund and the Pandemic Fund among institutions to be consolidated or closed within a decade, and named the WHO as an institution that should continue.

Germany is funding the first group to the tune of €1 billion to the Global Fund for 2026–28, and €600 million to Gavi over five years. At the same time, it is cutting its voluntary contributions to the WHO; only the mandatory dues are untouched.

Germany is not withdrawing from global health. It is wavering when it should be leaning in.

Nowhere is the lack of a coherent strategy clearer than on medicines. Anna Holzscheiter of TU Dresden calls Germany’s position “organised hypocrisy”: in Geneva, Germany argues for equity and public goods; in trade negotiations over patents and technology transfer, she argues, it blocks measures that would make those principles possible. When pressed, Germany points the finger at Brussels.

The German trap

The latest World Health Summit opens at the storied InterContinental hotel in Berlin on Sunday,

The health ministry cannot resolve the issue because it does not control the relevant policy. A senior official there told me that the ministry is “not in charge of IP. There are two other ministries that are really giving us a hard time here.”

The contradiction is visible in Germany’s own record. In April 2020 Merkel said a COVID-19 vaccine should be “a global public good” and produced “in as many places in the world as possible.” In May 2021, the Bundestag rejected a patent waiver by 498 votes to 117.

BioNTech’s founder emailed Merkel his thanks the same day. By June, Merkel was telling parliament that a waiver was the wrong approach.

Christine Godt, professor of economic law at Oldenburg, sees a structural reason for this. Germany is a corporatist state: policy is negotiated with organised interests, and pharmaceutical companies are among them.

On lobbying, she says: “All means are used: advisory, drafting, conferences.” Godt notes that a patent alone does not make a vaccine available. The know-how to manufacture it matters too. Technology transfer has been part of international trade policy for decades but has never been effectively enforced.

Germany can attach conditions to public money when it chooses to. In September it gave Sanofi €400 million to keep producing insulin in Frankfurt, with obligations on output and stockpiles. It attaches no such conditions to the public money it gives for vaccines and medicines meant for the world.

Walter Bruchhausen, a medical historian, describes the problem simply: “If you just give money, you don’t influence policies. That is the German trap.”

The World Health Summit shows the pattern. Almost everyone I spoke to said the same: an event of government patronage and corporate sponsorship, with side meetings priced from €10,000 to €45,000, is not where policy is made.

The Summit agrees: decisions, it told me, “are made by the governments and institutions within their respective mandates”; it provides “a public platform for the announcement of commitments.” It does not know how many invited participants failed to get visas, and says equitable participation is “not a finished task.” A platform is not a plan. Berlin funds it while cutting its voluntary support for the WHO.

Homework for the chancellor

Opening night at the World Health Summit in Berlin last year, which had some 3,000 registered attendees.

Give global health a mandate. Place an ambassador or coordinator in the Federal Chancellery, where the G7 and G20 sherpas already work, with the authority to coordinate the ministries, develop one strategy, and ensure it is implemented. In September, a study published by the Konrad-Adenauer-Stiftung, the foundation affiliated with the governing CDU, recommended exactly that, and the restoration of the parliamentary subcommittee.

Give the post measurable goals, an annual report to the Bundestag and independent evaluation. DEval already evaluates development policy and could do the same for global health. And involve people who work in the field: scientists, civil society and practitioners should help shape positions, not simply be invited to a round table twice a year or given a panel at the Summit.

Put conditions on publicly funded medical innovation. Public money should come with public-interest conditions, at home and abroad: a price ceiling, say, or a licence that allows others to use the technology. The pandemic agreement Germany negotiated obliges every party to adopt a policy on access conditions in publicly funded research, though it leaves the content to governments.

WTO rules, reaffirmed at Doha, let countries override patents to protect public health. Germany should use the room those rules provide rather than negotiate around it. The pharmaceutical strategy being rewritten in the Chancellery, due by year’s end, is the place to set these rules. Germany’s research ministry required similar conditions for neglected-disease grants in 2011. It never made them standard. 

Build partnerships for health sovereignty. The Accra Reset is one expression of a wider demand: governments across the Global South want control over their health financing and production. Germany should back the institutions those countries want strengthened: Africa CDC, national public health institutes, regulators and manufacturers, with the WHO setting common standards.

Germany’s most useful export may not be a patent but its Ausbildung ethos: the vocational and institutional training that builds skills and institutions which remain in place and grow locally. The RKI already works this way; Germany should expand that approach and let its partners define success.

Leadership that matters

Germany has long declined the role of a ‘leader’. That is changing.

Under pressure, it seems to be assuming that role for its armed forces, in the ambition to build “the strongest conventional army in Europe.” It has not yet assumed it for health.

A country that believes in international rules needs more than institutions. It needs to decide which institutions to defend, which norms to support and where to build lasting partnerships. National security also depends on human security. Germany is now increasing spending on the first while reducing capacity in the second.

The Bundestag will settle the budget in late November and can still restore the international health fund. The October Summit gives Germany a public stage to say what it wants to achieve. If it does not, the conclusion will be hard to avoid. There never was a plan. There was a chancellor. And she left.

About the author

Dr Unni Karunakara is a Senior Fellow at the Global Health Justice Partnership at Yale Law School in the US, and the Richard von Weizsäcker Fellow at the Robert Bosch Academy in Berlin. He was the interim director of the United Nations University International Institute for Global Health (UNU-IIGH) in 2024-2025, and international president of Médecins Sans Frontières (MSF) from 2010-2013.

Image Credits: World Health Summit, Clemens Bilan, World Health Summit, E. Fletcher/Health Policy Watch, David Ausserhofer.

US Embassy Chargé d’Affaires Mich Coker (left) and Zambia’s Minister of Finance, Situmbeko Musokotwane, sign the MOU.

Zambia and the United States finally signed a bilateral health aid agreement on Thursday – after a 10-month delay as the US pushed for better access to the country’s minerals and changes to mining and agricultural regulations in exchange for health aid.

In 2024, 84% of Zambia’s HIV programme was funded by the US President’s Emergency Plan for AIDS Relief (PEPFAR) – and 1.3 million Zambians are on antiretroviral medicine to keep their HIV in check.

But Zambian Minister of Foreign Affairs Mulambo Haimbe told reporters at the signing ceremony that the country is negotiating a separate critical minerals agreement with the US

“There was this [agreement] on health and another on critical minerals, and we were saying that these need to be decoupled, and this has been done,” Haimbe said, adding that the minerals agreement is still being negotiated.

Zambia is one of the world’s biggest copper producers and also has large deposits of lithium and cobalt.

In terms of the health memorandum of understanding (MOU), the US “intends to provide more than $1.5 billion over the next five years to support priority health programs in Zambia including HIV/AIDS, tuberculosis, malaria, maternal and child health, disease surveillance, and infectious disease outbreak response and preparedness”, according to the US Mission In Zambia.

The Zambian government has pledged to increase its domestic health expenditures by $975 million over five years.

Zambia’s civil service will also take over frontline health care workers currently supported by the US government, and the country will also take over procuring health commodities.

The US funding will also support the scale-up of Zambia’s health data systems, including ensuring the “interoperability of key programmatic data for HIV/AIDS, TB, malaria, and disease outbreaks tracked at scale over the long term”.

‘Inspiring advocacy’ ensures changes

Health activists have hailed the MOU, pointing out that the US has committed $504 million more in funding than in the previous draft agreement and that health aid is no longer conditional on US access to minerals.

Zambia’s co-financing requirements have also been reduced from $243 million in the original MOU  to $154 million, and it is no longer tied to compulsory sharing of pathogen information with the US for 25 years.

“An inspiring, coordinated campaign of advocacy, pressure and outcry from Washington to Lusaka secured meaningful changes in this deal,” said Asia Russell, who heads Health GAP, a global medicine access project.

While there are “still weaknesses” in the new MOU, Russell said the changes showed that “solidarity, public and private pressure, and the refusal by civil society to accept HIV and global health funding being used to blackmail Zambia into handing over its mineral wealth were all components essential for securing progress in the face of an administration seemingly intent on dismantling ambitious, accountable, transparent, and data-driven global health programmes.”

In contrast, Zimbabwe failed to renegotiate the terms of its proposed MOU with the US, and has lost all aid – the catastrophic effects of which are already evident in the country’s malaria, tuberculosis, HIV and maternal and child programmes.

US Embassy Chargé d’Affaires Mich Coker (left) and Zambia’s Minister of Finance Situmbeko Musokotwane (centre) display signed copies of the U.S.-Zambia health MOU while Minister of Health Prof. Roma Chilengi (right) applauds.

Transactional demands

Last December, the US announced that it had reached agreement with Zambia on “a plan that aims to unlock a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms.”

However, while the US signed several MOUs with other African countries around this time, a deal with Zambia did not materialise.

The MOUs are part of the US State Department’s “America First Global Health Strategy”, which is based on making the US “safer, stronger, and more prosperous” – including by enabling US companies access to business opportunities in healthcare delivery.

In February, Zambia acknowledged that part of the proposed health aid deal with the United States “does not align with the country’s interests”.

In March, The New York Times reported that the US was planning to use health aid as a bargaining tool to force the country to give it access to critical minerals.

It quoted a leaked memo from the US State Department’s Africa Bureau to Secretary of State Marco Rubio, stating: “We will only secure our priorities by demonstrating willingness to publicly take support away from Zambia on a massive scale.”

After the leak, Dr Mike Reid, PEPFAR’s chief science officer, resigned in protest over Zambia’s treatment.

“When life-saving health assistance, often beyond the immediate capacity of partner countries, is conditioned on unrelated commercial or strategic objectives, something essential is lost,” Reid wrote in a Substack post shortly before resigning.

Crippling effect on HIV services

Zambian Health Ministry leaders have described the chilling effects on their health services after changes to US foreign aid following Donald Trump assuming the US presidency in January 2025.

These include a “drastic decrease in the HIV care workforce”, clinic closures, the cessation of “most HIV prevention services”,  “disrupted logistics, supply chains, [and] data systems”, and the “ interruption of key services such as HIV testing, laboratory diagnostics, and surveillance systems”.

“Electronic medical record systems, which had been run with PEPFAR support, became inaccessible, including in clinics that had implemented a fully digital workflow without paper-based records on-site,” the health ministry leaders noted in the journal, Open Forum Infectious Diseases.

“This occurred because data clerks were terminated and typically instructed to return laptops to the implementing partner’s headquarters; others left computer hardware on-site but without the opportunity to transfer passwords, accounts, or informatics skills to other staff.”

The Ministry leaders also modelled the impact of the disruptions, noting that just three months’ worth of disrupted services would cause an additional 34,550 deaths and 54 863 new HIV infections – something that the ministry will now need to factor into its plans as it scrambles to resume paused HIV prevention services.

*Story updated to include Health GAP comments and links to the old and new MOUs.

Thermal screening at a port of entry in the Democratic Republic of the Congo.

The Kenyan man who died of Ebola this week travelled extensively through the Democratic Republic of Congo (DRC) and Uganda and sought medical care from mid-September – passing through several airport health screenings without detection, even two days before he died.

Dr Wessam Mankoula, head of health emergencies for Africa Centre for Disease Control and Prevention (CDC), presented a map of the man’s travels at a media briefing on Thursday, showing that he sought medical treatment at health centres in Bondo and Kasangani in the DRC from as early as 17 September.

The deceased travelled through at least eight towns and cities and took three flights while sick, his final journey being a flight from Entebbe in Uganda to Nairobi on 3 October. He was picked up at Nairobi’s Jomo Kenyatta International Airport by a family member who drove him directly to Nairobi Hospital, where he died of Ebola two days’ later.

His medical records indicate that he had been suffering from fever and skin rash, and was diagnosed with a staphylococcal skin infection. There was some suggestion that he might have erroneously been diagnosed wth Rift Valley Fever, a mosquito-borne disease.

The journey taken by Kenya’s first Ebola patient in the weeks and days before his death, as mapped by health authorities in the DRC, Uganda and Kenya.

By the time he reached Nairobi, “he was suffering from fever, sore throat, muscle pain, and also bleeding in some of the infection sites,” said Mankoula.

The World Health Organization (WHO) reported on Wednesday that the man’s temperature had been recorded as normal when he was screened on two separate occasions.

Mankoula said he was possibly taking antipyretic medication, which had masked his fever and urged travellers to be transparent about their symptoms to ensure they did not endanger others.

“Please, if you start having any symptoms related to Ebola, if you have been in touch with any confirmed cases of Ebola, report this to the health authorities in your countries,” Mankoula urged.

“If you start having fever, please don’t try to take drugs to mask those symptoms so that you can start crossing the borders. 

“When you reveal if you have any symptoms or signs related to Ebola, you are not only preventing further spread to other countries, but also you are protecting yourself first. When you seek medical care early, we see an improvement in the outcome. When you delay in seeking medical care, this is when we see worse outcomes.”

“Africa CDC is calling for vigilance, not panic,” Mankoula stressed, saying that co-operation between the three affected countries has enabled authorities to map the man’s movements and start tracing his contacts.

In response, Kenya has activated its public health emergency operations centre and a national task force led by the Ministry of Health

Mankoula also called for the strengthening of health screening measures at countries’ points of entry and points of exit. 

“We have tried, through thermal screening, through some of the questionnaires in the countries, to track the history of the travellers and also if they have any symptoms or signs. So this is helping the countries to take quick measures to identify any suspected cases quickly and deal with this.”

More than 8,700 cases have been reported in DRC with 4,205 deaths – a 48% case fatality rate. There has been a 24% decrease in Ituri in the past three weeks, and a 19% decrease in Nord-Kivu, although conflict in the province is affecting surveillance. 

 

Image Credits: Twitter: @MoetiTshidi.

Chinese Foreign Ministry spokesperson Mao Ning briefing reporters in Beijing, where she confirmed Song Li’s nomination and reiterated China’s commitment to multilateralism.
Chinese Foreign Ministry spokesperson Mao Ning briefing reporters in Beijing, where she confirmed Song Li’s nomination and reiterated China’s commitment to multilateralism.

Beijing confirmed the nomination of National Health Commission official Dr Song Li for WHO Director-General on Thursday (8 October). The move expands the candidate field to seven amidst severe geopolitical ruptures shaking up the agency, with experts warning this move could further heighten superpower tensions.

In announcing the bid, Chinese officials framed the candidacy around global solidarity and strengthening multilateralism.

“China’s decision to nominate Dr Song Li reflects China’s aspiration to work for a global community of health for all and demonstrates China’s firm support for multilateralism,” Foreign Ministry spokesperson Mao Ning told reporters during a press briefing in response to a question by Reuters.

Song was nominated by the People’s Republic of China as WHO DG candidate.

“If elected, it will help the WHO play a more positive role in promoting the health and wellbeing of all humanity,” she added.

Until late last month, Song served as Director-General of the Department of Women and Child Health in China’s National Health Commission. She is a physician-scientist trained at Peking University and Harvard, bringing over two decades of experience in maternal policy, epidemic response, and WHO technical advisory groups.

Observers note Song’s technical focus contrasts with established ministerial and diplomatic figures in the race.

Song bid spotlights China’s financial weight

China ranks fourth in overall WHO funding for 2025-2026 at $320 million, driven overwhelmingly by mandatory assessed dues rather than voluntary contributions.
China ranks fourth in overall WHO funding for 2026-2027 at $320 million, due to the size of its mandatory assessed dues rather than voluntary contributions.

Song’s nomination by the People’s Republic of China comes as WHO manages massive budget cuts following the declared withdrawal of the United States in January 2025. Owing $280.9 million in unpaid arrears, WHA member states did not formally recognize the move at the May 2026 World Health Assembly.  But due to the unpaid dues, the US still faces the suspension of its voting rights at the 2027 World Health Assembly when the next WHO Director-General will be elected.

Global health policy experts observe that Beijing aims to fill the leadership void left by Washington’s withdrawal. According to official numbers on the WHO website, China’s total projected financial contribution to the WHO for the 2026-2027 biennium stands at $320 million through August, making it the largest state contributor in terms of assessed funding after the US withdrawal.

Among state donors, China’s funding is exceptionally concentrated in mandatory assessed dues, contrasting with traditional high-income donors from Europe, the Americas and western Asia, which distribute significant portions of their funding across core voluntary, thematic, and specified voluntary channels.

When compared against other major contributors, China ranks as the fourth-largest overall donor to the WHO, trailing only the Bill and Melinda Gates Foundation, the European Commission, and the World Bank, while sitting ahead of the United Kingdom, the GAVI Alliance, and Germany. While European Union Member States hold 27 votes in the WHA, the EU is not likely to vote en bloc, and two European nominees in the race could split their support.

Health Policy Watch reached out to the WHO asking to confirm the nomination and whether China had paid its dues for 2026 in full, but did not receive a response ahead of publication.

High geopolitical stakes for WHO

Lawrence Gostin doesn't see a global appetite for a Chinese DG candidate.
Lawrence Gostin doesn’t see a global appetite for a Chinese DG candidate.

One leading US global health expert voiced serious doubts that a Chinese candidacy will indeed shake up the final race because of the high geopolitical stakes for the WHO.

“In the aftermath of COVID-19, I do not think there is a global appetite for a Chinese candidate for WHO Director-General,” Lawrence Gostin, professor of global health law at Georgetown University, told Health Policy Watch.

“A Chinese candidate would heighten geopolitical tensions, putting the WHO in a difficult and vulnerable position,” Gostin added. “It would also make rejoining the WHO far more difficult for the US, even under a Democratic administration.”

The friction stems from increased geopolitical competition between the two superpowers and a lingering political fallout over COVID-19 transparency and initial outbreak reporting. Gostin noted that bipartisan opposition in Washington and a lack of civil society support create formidable hurdles for Song across both North America and Europe.

European reactions, however, remain more divided. While one senior European official warned that a successful Chinese bid would test the WHO’s fundamental legitimacy and independence, others were less alarmist, noting that Beijing’s diplomacy remains “very nuanced” and that China is viewed in Europe as a partner as well as a competitor.

Besides geopolitical scrutiny, China’s candidacy also faces structural UN hurdles regarding geographic distribution. With Dr Margaret Chan, a dual Canadian and Chinese national from Hong Kong, having served two terms as WHO Director-General from 2007 to 2017 and the Chinese national Qu Dongyu currently heading the Food and Agriculture Organization, member states may resist concentrating more UN agency leadership into the hands of one country.

BREAKING: China Has Nominated Candidate for WHO Director General Whose Name Remains Undisclosed

Note: This piece has been updated regarding Song’s position, Dr Margaret Chan’s term dates, and WHO budget cycle data.

Image Credits: Ministry of Foreign Affairs People’s Republic of China, WHO, WHO/HPW.

Jiho Cha, the Korean parliamentarian who is not running for WHO Director General

I sought to lead the World Health Organization (WHO) because the rules of intelligence are becoming the rules of health. My name will not be on the ballot. The responsibility remains. I will now work to organise the political and economic power needed to put intelligence at the service of humanity – and to keep it from turning against us.

Nominations for the next WHO Director-General closed on 24 September. Seven names are on the list. Mine is not. Those who received me as a candidate this summer deserve more than a sentence. The short version is that I chose a task I judged more urgent than the leadership of any single institution. The longer version is this essay, because the vision was never about me, and the question at its centre still awaits an answer from any of the six.

The question is simple to state, and it has been asked of every technology that has ever entered the clinic. The global health architecture is about to acquire a new layer of intelligence. For whom will it work, and under whose control? And, more urgently now: who will keep it from turning against us?

What the field taught me: Social, political and intelligence determinants of health

Access to nutritious, fresh foods, a critical determinant of health.

I came to that question slowly, through two kinds of work that rarely speak to each other.

More than 20 years ago, my first humanitarian posting as a physician was at Hanawon, the centre where people who have escaped North Korea spend their first months in the South. 

For three years I examined people who had crossed borders on foot and spent years in hiding. They arrived with tuberculosis and trauma, and with structural violence that had settled into the body. 

But my clinic was the end of their illness’s story, not its beginning. The social conditions that had made them ill lay years upstream: a famine that was political before it was agricultural, borders that turned flight into a crime, a stateless existence in which seeing a doctor meant risking deportation. What I treated were the sediments of a social order – the social determinants of health, arriving one body at a time.

With Médecins Sans Frontières, I followed those conditions back to their source: the borderlands people had fled, and later, with other humanitarian colleagues, to the Kashmir earthquake, the jungles of Papua New Guinea, and the refugee camps of the Democratic Republic of Congo. 

There I learned a lesson the textbooks phrase too politely. Illness in a crisis is rarely an accident of biology. It is the body’s registration of decisions made elsewhere. A woman denied even refugee status turns to a trafficker not because she misjudges the risk, but because every legal door has closed and return is the one certainty she cannot survive. The well-meaning people in white vehicles – I was one of them – too often arrive without the history that made the poverty they came to relieve, mistaking colonial residue for local misfortune.

Twenty years later, the citizens of Osan, a working city south of Seoul, sent me to the National Assembly, and there I learned the other half of the story. I watched the grief of Itaewon, where 159 people died in a single night, bent to political need and then erased. I watched the martial law decree of 3 December 2024 outlaw the Assembly in one clause and order striking doctors back to their wards in another – one text aimed at legislators like me and physicians like me.

And on the presidential campaign and the National Planning Committee, among the few who write national strategy, I learned how a line in my policy book becomes a ministry – or quietly a footnote no one answers for. 

Behind every failure of health care I had witnessed stood not a shortage but a choice: a political determinant. Power decides not only who is treated, but who is recognised as ill, and who has the power to judge whether or what treatment is provided.

‘Intelligence’ – the determinant behind the determinants

Meeting a child waste picker in Cambodia.

Between the social and political determinants, a third took shape, and it ran deeper than either. The resource on which health systems have depended longest, and which they have distributed most unequally, is neither medicine nor money. It is human judgement: the capacity to recognise who is ill, to decide what should be done, and to act. I call the conditions that govern the social distribution of that judgement the intelligence determinants of health. 

Across much of the world, a single nurse makes the decisions on which 10,000 lives may depend, with no one to consult and no second opinion within a day’s travel. Economists, scientists and policy experts are distributed across the world just as unevenly, and that distribution may itself be a determinant of the social and political conditions I had spent 20 years treating – the determinant beneath the determinants.

For the first time, a machine can carry a part of that judgement to places it has never reached. Governments and companies will decide within the next few years whether it reaches that nurse or only the hospitals that can pay – and they will decide much of it in private contracts whose terms no one outside the signing room will ever read: an old pattern in a new form, the determinants of health settled where the people they determine cannot see.

What I stood for: Climate, Health, and AI

Global AI hub launch in Seoul, Korea in May 2026

I wanted WHO to write the rules for this emerging layer of intelligence before the market did. In an emergency, the interval between a need and a standard is filled by whoever arrives first. WHO is the one institution every health ministry listens to, but the distance between a principle agreed in Geneva and a contract signed in a ministry is where the future of health care is being settled.

For a decade, since AlphaGo defeated the world’s best Go player,Lee Sedol, born on my mother’s island, I have worked on this new layer of intelligence from the outside: on AI-augmented health systems for low-resource settings, and more recently on Korea’s new societal model, the “AI Universal Basic Society” (AI UBS), which treats intelligence as public infrastructure for essential services, beginning with health care. 

In May, nine UN agencies including WHO, launched the Global AI Hub, a shared operational campus of the UN system, and in September Korea put both proposals before the General Assembly.

But WHO itself was not moving at the speed the moment demanded. Member states cut its base budget for 2026–27 from $5.3 billion to $4.2 billion, and development assistance for health fell to its lowest level in roughly 15 years. An organisation that has lost a fifth of its budget and many of its ablest people does not run towards new fields; it defends the ones it has. Meanwhile the largest technology companies were signing national-scale agreements for health and education, most on undisclosed terms.

So I did what a physician does when a referral is taking too long. I went to the patient myself. In July, I declared.

The core of my policy manifesto, One Doctor, Eight Billion Patients, is a single proposition: Universal Intelligence Coverage (UIC) for health. Universal health coverage asks whether people can receive care without being ruined by the cost. UIC asks whether judgement – human, machine or both – reaches everyone, and who answers when it fails. 

I proposed a “1.5-tier” model of primary health care: frontline workers equipped with AI decision support and supervised remotely by human professionals, with responsibility for diagnosis and treatment kept firmly with people.

Climate finance was the second strand. Less than 1% of it reaches health. I argued that a climate-resilient health system is itself a frontline mechanism of adaptation, and proposed that WHO use the Green Climate Fund accreditation it secured this year to channel roughly $1 billion into primary care without drawing a dollar from its shrinking core budget. 

The larger point was about dependence. Global health has run for decades on voluntary, earmarked money from a handful of governments, and the past two years have shown how quickly that base erodes when one of them turns inward. 

Blended finance is the way out: climate financing anchoring the public health layer, the private capital now pouring into the AI transition financing the intelligence layer above it, and public terms binding both to public goals.

Over 10 weeks I took these ideas to three continents – Africa, Asia and Europe – and to the leaders of their regional organisations. What we built together rests on one principle: regional health sovereignty – a decolonised global health architecture, powered by a new layer of intelligence and a new mechanism of finance. 

In Africa, it is “African AI for African health”, running on African infrastructure and answering to African law. In the Pacific Islands it is the “Pacific AI Initiative”, a regional platform for climate-resilient health systems. All want to build, not merely to buy.

African AI needs to run on African infrastructure and answer to African law.

After stepping back

I believe the diagnosis was right and the prescription was ready. I had been nominated by the Parliament as a WHO candidate for DG. But at the last minute, circumstances changed.  

The responsibility now passes to one of the other seven candidates, and I wish each of them well. Whoever becomes Director-General will find in me a partner. But the campaign taught me something I had not fully grasped when it began.

Meeting heads of government, frontier researchers and leaders of AI and biotechnology companies, I heard the same assessment with increasing frequency: the convergence of autonomous AI and biotechnology is entering a stage at which it could generate an existential threat of a new kind: a pandemic made by humans and machines together. 

The frontier laboratories now say so themselves: by their own published assessments, their latest models have reached the thresholds at which they could materially assist biological misuse, and the companies that build them ask publicly to be regulated. A risk I had been warning about for years was arriving far faster than I had expected. The window is closing: capability is advancing by the quarter, public control by the decade.

These are not two separate agendas. Bringing validated intelligence to a rural clinic and keeping unvalidated intelligence from harming the world are two answers to the same question – for whom, and under whose control, does intelligence work? 

But this answer lies beyond WHO’s reach. Responding to a pandemic, whatever its origin, is WHO’s mandate. Governing the roots of this risk – the race in frontier AI and its fusion with biotechnology – belongs to no institution at all. 

As with the nuclear competition of the last century, the world has no mechanism to slow a race centred on the United States and China, and the voice of industry overwhelms that of states. The world has visions and forums enough; it has no institution and no budget line for the AI society that is already arriving.

What it does have is the makings of a coalition. The Global South champions and the middle powers that hold technology and finance can, together, assemble the strength to shape that AI society. I have concluded that this work was more urgent than any position in any organisation. Over these months, leaders serving and former – in governments, international organisations, the media and academia – reached the same conclusion and asked me to help convene such a coalition. I In my own country, the expectation came from the highest level of government. I chose it.

A humanitarian learns early to go not where the doctors already are, but where there are none. The WHO post will be well filled; this work was more pressing, and almost no one was standing in line for it.

What I will do at the existential crossroads of the AI society

An individual viewing glowing numbers on a screen, symbolising artificial intelligence.
I will organise a global coalition to become an AI buyer, with the power to negotiate, purchase, legislate and govern.

Most proposals for AI governance begin with visions and institutions. I have sat in enough of those rooms to know how slowly they fill. Mine begins with a buyer – and in a market of scattered ministries, a buyer first has to be assembled. In a revolution led by private actors, the power a public actor can use fastest is to decide what it buys and on what terms.

Outside the few countries that build the intelligence infrastructure itself, the Global North will mostly use AI to replace human labour in systems that already exist, and substitution alone does not make a new economy.

In the Global South, the need has always outrun the supply–the clinic without a doctor, the classroom without a teacher, the household without a bank–and intelligence that can finally meet it creates a new economy rather than replacing one: a trillion-dollar market in which the buyer, not the supplier, should set the terms–and no one has yet organised a hundred fragmented buyers into one.

That is the work I will do, and the order is the strategy. Ask industry to regulate itself before you hold any market leverage, and the rules it writes will hold you. I will organise a coalition that can negotiate, purchase and legislate, govern–in that order.

First, a Planetary Intelligence Network, solidarity for sovereignty. Sovereignty over intelligence will not be won one ministry at a time; only a network of leaders who can decide can build it. I will convene it within months, not years. Any leader who shares these concerns – sovereignty over external intelligence, existential risk – has a seat. This is a network, not a bloc, and its first effect is simple: ministries that have always faced the same supplier alone begin to negotiate as one.

Second, New 3 by 5, collective purchasing power. Twenty years ago, Dr Lee Jong-wook set the world a target he called 3 by 5: three million people on HIV treatment by 2005. I propose a new 3 by 5: three million AI-augmented primary health care (PHC) workers within five years. We will augment first the community health workers, nurses and clinical officers who provide most first-contact care, raising their clinical and epidemiological capability toward that of a primary care physician, under remote human supervision. 

This is physician-level judgement arriving in three million places that have never had it. Connected across a continent, AI-augmented PHCs become a connected health system and pandemic preparedness–and a single buyer large enough to set terms. If a pandemic made by humans and machines ever begins, its first case will present not to a frontier lab but to one of them. Access and early warning are one investment.

Third, a Public Intelligence Compact, collective regulating power. A buyer of that size can set terms. The Compact is one set of conditions for any system that shapes a decision about a person in a public service: independent validation, data management under national law, continuity of service, the right to audit, transparent pricing. As a declaration, these are pieties; as a procurement rule, they are the law of the market. 

The Compact is neutral as to flag: any company that meets the terms is welcome. Sovereignty means a country can choose, question, change and, when necessary, leave the systems it uses. Its companion I call Firebreak – the line a fire does not cross. We cannot put out the fire of frontier development, but we buy the very models that could start one, and a buyer can set conditions today: no DNA synthesis order unscreened, no model in a public service unevaluated, no incident unreported. 

The Compact is the first line of defence, Firebreak the last, and the three million workers watching for the first spark are the sensors in between.

Fourth, a Public Intelligence Foundation and Existential Risk Council, a blended governance. This step evolves with purchasing power and regulating power. The Foundation is a shared operational platform with the global AI companies that will translate private AI back into public intelligence on the Compact’s terms. 

Beside it, and firewalled from it, stands the Existential Risk Council, independent of the foundation’s money, because a body that depends on industry cannot also judge its dangers. It will make independent evaluation of existential risks such as biological misuse–with incident reporting and synthesis screening–the price of entry for every model and the laboratory that trained it. The council will define itself against no state.

None of this replaces the United Nations. The network brings will, leverage and pace; the UN brings implementation and universality–the Global AI Hub’s agencies beyond health, and WHO for the clinical standard, which we will adopt, not rival. I know how this fails: a foundation captured by its funders, pilots that vanish with the donor cycle, and the oldest failure of all–help that arrives without asking the people it is for.

That is the work I am committing to lead.

Eight billion for one patient.

Jiho Cha is a humanitarian physician, global health scholar and Member of the National Assembly of the Republic of Korea, and co-chairs the Lancet Commission on Sea-Level Rise, Health, and Justice. For two decades, he has worked with marginalised populations in the Middle East, Africa and Asia, and with the displaced people caught between them. He was Professor of Humanitarian Studies at the University of Manchester and of AI and Future Strategy at KAIST, and designed Korea’s AI Universal Basic Society framework and the Global AI Hub, a joint campus of nine UN agencies. His policy manifesto, One Doctor, Eight Billion Patients, was prepared for his candidacy for WHO Director-General. The views expressed are his own.

Image Credits: Jiho Cha, Ron Lach via Pexels.

Dr Tedros addressing the media briefing.

The World Health Organization (WHO) has asked the Russian government for more information about the death of an employee at a Siberian plague research unit, including details about the laboratory tests conducted on her, the WHO Director-General told a media briefing on Thursday.

The WHO has also asked Russia for more details about the public health measures it has imposed, the health status of the woman’s contacts, and whether a second employee has been infected with “pneumonia of undetermined cause”, said Dr Tedros Adhanom Ghebreyesus.

This follows reports on Monday of the death of a 27-year-old female employee at the Irkutsk Anti-plague Research Institute of Siberia and the Far East – possibly of pneumonic plague.

The employee was hospitalised at Shelekhov Hospital on 29 September with symptoms of pneumonia, placed on a ventilator and died a few days later, according to media reports.

Tedros said that the WHO had sent queries to Russia on Saturday, and received a report on Wednesday that “no case of plague had recently been reported in the Irkutsk Oblast” where the research unit is, and that they had “placed about 200 [of the woman’s] contacts in quarantine”.

WHO has also offered Russia technical support related to “plague and lab biosafety and biosecurity”, Tedros said, adding that “we don’t yet have the full picture of this event, and we are not able to conduct a full risk assessment”.

Broken test tube?

Dr Maria Van Kerkhove, WHO director of epidemic and pandemic management.

Some media reports say the employee died after breaking a test tube in the laboratory, but Dr Maria van Kerkhove, WHO director of Epidemic and Pandemic Management, said that employees working in such laboratories would wear personal protective equipment (PPE) and be vaccinated against various diseases.

“We are following up on what type of PPE would be used, and under which conditions? What were they doing with these pathogens?” said Van Kerkhove.

“If there was a lab incident in this lab, there are procedures that must be followed in terms of the assessment that they do in the lab. There would be post-exposure prophylaxis, for example, for this individual. They would probably run tests, so there’s more to come as it relates to what actually happened,” she explained.

“What we have been told is that [Russia] has no case of plague registered in this area, and that no high threat pathogens were detected. So clearly, we would like more information to understand which laboratory tests were conducted, which pathogens were evaluated, and if this individual didn’t die from plague, then then how did she die?” Van Kerkhove added.

Plague is a severe, life-threatening infection caused by the bacterium Yersinia pestis and there are two types: bubonic and pneumonic. 

However, Van Kerkhove said there are thousands of cases of suspected plague every year around the world: “Between 2019 to 2025, 10 countries reported almost 4,000 suspected human plague cases and 423 deaths.”  

Central Asia is the hot spot, and people are infected by bacteria carried by small rodents.

“Sometimes there are small, sporadic outbreaks. Plague is caused by a bacteria. There are antibiotics that can treat this. So if anyone does have an infection with plague, it can be treated.”

International Health Regulations requirements

In terms of the International Health Regulations (IHR), WHO member states are legally obliged to assess public health risks and notify the WHO of any event that may constitute a public health emergency of international concern (PHEIC) within 24 hours of assessment.

Although the WHO submitted its queries to Russia in terms of the IHR on Saturday, it took the government more than three days to respond.

Dr Silvio Ciobanu from WHO’s European region and an IHR expert said countries have to answer four key questions in terms of the IHR: “How severe is the public health impact? Is it unusual and expected? Does it pose a risk of international spread? And does it pose a risk of trade or travel restrictions?”

Ciobanu added that the IHR are “very explicit that a response is expected within 24 hours, and then after that, state parties may require a little bit of extra time to collect all the additional information”.

Thick smog blankets the skyline of Bangkok, Thailand, in 2018.
Thick smog blankets the skyline of Bangkok, Thailand.

International development lenders committed $4.7 billion in 2024 to projects aimed explicitly at reducing air pollution, less than 1% of all international development finance, according to an annual analysis published Tuesday by the Clean Air Fund (CAF).

That was up 58% from $3.0 billion in 2023, nearly matching the 2022 peak of $4.8 billion. A broader measure, which also counts projects where cleaner air is a co- benefit, fell 6% to $28.7 billion, the first annual decline in five years. Five of the ten most polluted countries got less than $2 per citizen, and most of the money came in the form of loans, the analysis found.

Air pollution causes 7.9 million premature deaths a year, nine in ten of them in low- and middle-income countries, according to Health Effects Institute figures. It costs the equivalent of nearly 5% of global GDP, the World Bank estimates, and targeted policies could halve the number of people exposed to dangerous levels by 2040, with economic benefits of up to $2.4 trillion.

“Funding remains worryingly low, concentrated on a limited number of places, and misaligned with countries facing the greatest burden,” said Sean Maguire, executive director for strategic partnerships at CAF.

Top 10 polluted countries and their total air quality funding, 2024.

The data analysed stops in 2024, before the largest annual drop in development aid on record hit the following year. Development assistance for health fell by more than a fifth in 2025, to $39.1 billion, its lowest level in over 15 years, according to estimates by the Institute for Health Metrics and Evaluation (IHME). US health aid fell 67%.

Even before the cuts, air pollution drew little donor money relative to its toll, compared with causes such as food security, humanitarian relief or climate finance. Foundations gave it less than 0.1% of their global giving between 2019 and 2023, a separate CAF analysis found.

“Recent gains remain fragile,” the report says. “The challenge is whether these gains can be sustained and scaled amid shrinking aid budgets.”

The CAF report, produced with Climate Policy Initiative (CPI), tracks 2020-2024 commitments by development banks and donor governments. It excludes domestic budgets and private finance, and nearly nine in ten dollars it counts are loans.

“With development budgets under growing pressure, clean air objectives must be built into wider development investment, so every dollar works harder and delivers benefits for health, climate and economies at the same time,” Maguire said.

Most polluted countries left behind

South Asia receives nearly a third of all air quality funding (2020-2024).

Pakistan, Nepal, Myanmar, Cameroon and the Democratic Republic of Congo, five of the world’s ten most polluted countries, each received less than $2 per person in air quality funding in 2024. India, the second most polluted, was the exception, drawing 19% of all air quality funding that year.

“Air quality funding is not going where pollution exposure and health risks are greatest,” Maguire said.

Pakistan, ranked third for exposure to fine particulate matter (PM2.5), received about 3 cents per person. Between 2020 and 2024, it received $1.7 billion in what CAF calls fossil fuel-prolonging funding, nearly three times the $0.6 billion it received for all air quality projects combined.

Bangladesh, the most polluted country in the ranking, was the largest recipient of fossil fuel-prolonging funding over the five years, at $3.7 billion. Bangladesh’s fossil fuel funding fell 96% in 2024, to $113 million, the report found. Over the five years, it received $7.8 billion in air quality funding.

“Our analysis shows that money is not yet consistently following need, and that countries facing some of the highest pollution levels often have the least access to finance,” said Barbara Buchner, chief executive of CPI.

A wide tent for what counts as clean air funding

Projects that make no mention of air quality made up 84% of the air quality funding CAF counted in 2024.

CAF and CPI find these co-benefit projects through keyword searches of project descriptions in OECD and development bank data, projecting a clean air benefit from the type of project. The methodology captures investments in public transportation like buses, railways and metro lines, wastewater plants and networks, solid waste, household energy efficiency, food waste and soil health. It does not check whether individual projects actually cut pollution.

Transport accounted for 62% of all air quality funding over the five years, with railways and public transport alone making up $53 billion. Two loans worth $5 billion for a high-speed rail line between Mumbai and Ahmedabad made up 14% of South Asia’s air quality funding.

“Investment in railways, public transport and cleaner mobility is demonstrating how better connectivity and economic development can go hand in hand with cleaner air,” said Fu Lu, CAF’s regional director for Southeast Asia. “We need these benefits to be shared by many more people and places.”

Because co-benefit funding tracks wider lending for transport and infrastructure, its growth provides only mixed signals about whether funders are prioritizing clean air specifically.

Total air quality funding, co-benefit projects included, has held at 5.6% of international development funding across the last two five-year periods, while the outdoor share slipped from 0.8% to 0.7%.

The narrower outdoor category leans on similar projects. Under the keyword rules CAF published last year, a transport or water project counts as explicit clean air funding if its description also mentions air, health or exposure. Ten projects made up 53% of outdoor funding over 2020-2024, seven of them rail or public transport, mostly metro lines.

CAF itself found “no structural shift towards explicitly targeting air quality improvements” over the medium term.

Loans dominate co-benefit finance

Loans made up 89% of the $124.6 billion in air quality funding between 2020 and 2024, about $110 billion. Grants accounted for 7.7%. Co-benefit projects, which make no mention of air quality, made up $108.7 billion of the total.

Concessional funding fell from $19 billion to $12 billion, while non-concessional funding rose from $12 billion to $17 billion, 58% of the total. Concessional loans carry below-market interest but still have to be repaid. In 2024, the balance tipped further toward market-rate lending.

In CAF’s figures, which follow OECD aid classifications, concessional finance counts as aid, and aid budgets are shrinking, with the OECD projecting a further 5.8% drop in 2026. The reliance on loans in the donor landscape may put air quality funding beyond reach for countries already carrying heavy debts, according to CAF’s analysis.

Official development assistance from OECD donors fell 23.1% in real terms in 2025, to $174.3 billion, according to preliminary OECD data, as the United States cut its aid by 56.9%.

Across the global South, debt service is absorbing 45% of government revenue in 2025 and exceeds combined spending on education, health and social protection by 20%, according to Development Finance International’s Debt Service Watch.

A narrow measure of fossil fuel finance

About $1.2 trillion is expected to flow into oil, gas and coal in 2026, according to the International Energy Agency’s annual investment report. Governments plan to produce 120% more fossil fuels in 2030 than would be consistent with limiting warming to 1.5°C, according to the 2025 Production Gap Report.

The International Monetary Fund puts explicit fossil fuel subsidies at $725 billion in 2024. Implicit subsidies, three-quarters of them the unpriced cost of air pollution and climate damage, add $6.7 trillion. Removing both would mean 1.1 million fewer premature deaths from air pollution, the IMF estimates.

Against those sums, the report counted $4.7 billion in what it calls fossil fuel-prolonging development finance in 2024, down 48% from 2023, and said that put it level with outdoor air quality funding.

The report counts only international public development finance recorded in OECD data, and only projects that build polluting assets, such as power plants, pipelines and airports, or that promote polluting activities.

Private banks, domestic state spending, guarantees, most export credit and fuel subsidies fall outside it, and road building was dropped from the count this year.

G20 governments and multilateral development banks provided at least $47 billion a year in international public finance for oil, gas and coal between 2020 and 2022, according to the campaign group Oil Change International. About 65% came through export credit agencies, which CAF’s figures largely leave out.

The report warns that continued investment in long-lived fossil fuel assets risks “lock-in to a fossil fuel-dependent development pathway.” It also acknowledges that such funding can support energy access and security in developing countries.

Last year’s edition urged donors to end funding for fossil fuel-prolonging projects. None of this year’s five recommendations mentions fossil fuels.

Image Credits: urf/Getty Images via Canva.